222 related articles for article (PubMed ID: 22789650)
1. [Intravitreal ranibizumab injection for the treatment of idiopathic choroidal neovascularisation in young patients].
Ouhadj O; Degheb N; Idir S; Nebab A; Nouri MT
J Fr Ophtalmol; 2012 Sep; 35(7):514-22. PubMed ID: 22789650
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration.
Ladas ID; Chatziralli IP; Kotsolis AI; Douvali M; Georgalas I; Theodossiadis PG; Rouvas AA
Ophthalmologica; 2012; 228(2):93-101. PubMed ID: 22571933
[TBL] [Abstract][Full Text] [Related]
4. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
Zhang H; Liu ZL; Sun P; Gu F
Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
[TBL] [Abstract][Full Text] [Related]
6. Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.
Erol MK; Ozdemir O; Coban DT; Ceran BB; Bulut M
Semin Ophthalmol; 2014 Mar; 29(2):108-13. PubMed ID: 24409939
[TBL] [Abstract][Full Text] [Related]
7. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of treatment efficacy of intravitreal ranibizumab injections in patients with wet type of AMD.
Lubiński W; Mozolewska-Piotrowska K; Krasodomska K; Penkala K; Kaźmierczak B; Karczewicz D
Klin Oczna; 2012; 114(3):187-93. PubMed ID: 23373399
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month follow-up.
Lorenzo D; Arias L; Alcubierre R; Pujol O; Caminal JM; Rubio M; Català J; Garcia-Bru P; Arruga J
Ophthalmologica; 2011; 226(3):103-9. PubMed ID: 21720153
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome.
Ruiz-Moreno JM; Montero JA; Gomez-Ulla F; Ares S
Br J Ophthalmol; 2009 Apr; 93(4):448-51. PubMed ID: 19091851
[TBL] [Abstract][Full Text] [Related]
11. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results.
Mimoun G; Caillaux V; Querques G; Rothschild PR; Puche N; Souied EH
Retina; 2013 Mar; 33(3):513-21. PubMed ID: 23400081
[TBL] [Abstract][Full Text] [Related]
12. Two-year outcome of intravitreal injections of ranibizumab for myopic choroidal neovascularization.
Wu TT; Kung YH
J Ocul Pharmacol Ther; 2014 Dec; 30(10):837-41. PubMed ID: 25162313
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal ranibizumab for choroidal neovascularization in angioid streaks.
Mimoun G; Tilleul J; Leys A; Coscas G; Soubrane G; Souied EH
Am J Ophthalmol; 2010 Nov; 150(5):692-700.e1. PubMed ID: 20719301
[TBL] [Abstract][Full Text] [Related]
14. [Intravitreal injections of ranibizumab in treatment of large peripapillary choroidal neovascularization].
Nochez Y; Le Lez ML; Pisella PJ
J Fr Ophtalmol; 2009 Jan; 32(1):25-31. PubMed ID: 19515310
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum.
Finger RP; Charbel Issa P; Ladewig M; Holz FG; Scholl HP
Br J Ophthalmol; 2008 Apr; 92(4):483-7. PubMed ID: 18369065
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with intravitreal injection of ranibizumab and reduced fluence photodynamic therapy for choroidal neovascularization secondary to angioid streaks: preliminary clinical results of 12-month follow-up.
Artunay O; Yuzbasioglu E; Rasier R; Sengul A; Senel A; Bahcecioglu H
Retina; 2011; 31(7):1279-86. PubMed ID: 21394063
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal ranibizumab therapy versus photodynamic therapy for idiopathic choroidal neovascularization: a comparative study on visual acuity, retinal and choroidal thickness.
Shi X; Wei W; Zhang C
Chin Med J (Engl); 2014; 127(12):2279-85. PubMed ID: 24931242
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
Lai TY; Chan WM; Liu DT; Lam DS
Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
[TBL] [Abstract][Full Text] [Related]
19. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome.
Ruiz-Moreno JM; Arias L; Montero JA; Carneiro A; Silva R
Br J Ophthalmol; 2013 Nov; 97(11):1447-50. PubMed ID: 24026146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
